Abstract: The invention relates to B-catenin, and to the use of compounds which can affect B-catenin translocation within the cell, for use in treating B-catenin/Wnt-signaling-related disorders, such as osteoporosis, cancer or diabetes. The invention extends to pharmaceutical formulations and compositions comprising such compounds.

Abstract: The present inventors have identified cancer associated mutations in plexinB1, which is a transmembrane receptor that mediates semaphorin signaling. The frequency of plexinB1 mutations, in particular in prostate and breast cancer, indicates that plexinB1 may be useful in the screening and diagnosis of cancer and as a drug target in the development of anti-cancer therapeutics.

Abstract: A light control system and method for a film viewer (10). The viewer (10) includes an infrared emitter (50) with an infrared detector (52) in communication with a microprocessor (34). When a radiograph (40) is inserted within the film viewer (10), the radiograph (10) is interposed between the emitter (50) and detector (52). The microprocessor (34) detects a change in the emissions sensed by the detector (52) and illuminates the viewer (10). The invention also provides a film holder (16) that includes a plurality of rollers (60) interposed between the holder (16) and the screen (14).

Abstract: A light control system and method for a film viewer (10). The viewer (10) includes an infrared emitter (50) with an infrared detector (52) in communication with a microprocessor (34). When a radiograph (40) is inserted within the film viewer (10), the radiograph (10) is interposed between the emitter (50) and detector (52). The microprocessor (34) detects a change in the emissions sensed by the detector (52) and illuminates the viewer (10). The invention also provides a film holder (16) that includes a plurality of rollers (60) interposed between the holder (16) and the screen (14).

Abstract: Compounds of the general formula (1) are inhibitors of the reuptake of norepinephrine. As such, they may be useful for the treatment of disorders of the central and/or peripheral nervous system.

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, which are useful for the inhibition of the uptake of one or more physiologically active monoamines (serotonin, norepinephrine, and dopamine).

Abstract: This application relates to a compound of formula I (or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor.

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, which are useful for the inhibition of the uptake of one or more physiologically active monoamines (serotonin, norepinephrine, and dopamine).

Abstract: The present inventors have identified cancer associated mutations in plexinB1, which is a transmembrane receptor that mediates semaphorin signaling. The frequency of plexinB1 mutations, in particular in prostate and breast cancer, indicates that plexinB1 may be useful in the screening and diagnosis of cancer and as a drug target in the development of anti-cancer therapeutics.

Abstract: N,N-disubstituted 4-amino-piperidines of the general Formula (I) are inhibitors of the uptake of serotonin and/or norepinephrine and/or dopamine. As such, they may be useful for the treatment of disorders of the central and/or peripheral nervous system.

Abstract: There is provided a heretoaryloxy/thio 3-substituted propanamine compound of formula (I) wherein A is selected from —)— and —S—; X is selected from phenyl optionally substituted with up to 5 substituents each independently selected from halo, C1-C4 alkyl and C1-C4 alkoxy, thienyl optionally substituted with up to 3 substituents each independently selected from halo and C1-C4 alkyl, and C2-C8 alkyl, C2-C8 alkenyl, C3-C8 cycloalkyl and C4-C8 cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl —S(O)n— where n is 0, 1 or 2, —CF3, —CN and —CONH2; Y is selected from dihydrobenzothienyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, naphthyridyl, and thienopyridyl, each of which may be optionally substituted with up to 4 or, where possible, up to 5 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n— where n is 0, 1 or 2, nitro acetyl, —CF3, —SCF3 a

Abstract: There is provided a compound of formula (I) wherein A is selected from —O— and —S—; X is selected from C2-C8 alkyl, C2-C8 alkenyl, C3-C8 cycloalkyl and C4-C8 cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n— where n is 0, 1 or 2, —CF3, —CN and —CONH2; Y is selected from phenyl, naphthyl, dihydrobenzothienyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, naphthyridyl, thienopyridyl, indanyl, 1,3-benzodioxolyl, benzothienyl, indolyl and benzofuranyl, each of which may be optionally substituted with up to 4 or, where possible, 5 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n— where n is 0, 1 or 2, nitro, acetyl, —CF3, —SCF3 and cyano; and when Y is indolyl it may be substituted or further substituted by an N-substituent selected from C1-C4 alkyl; Z is selected from H, OR3 or F, wherein R3 is selected from H, C1-C6 alkyl and phenyl

Abstract: This application relates to a compound of formula I (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.

Abstract: Compounds of formula (I) where R2, each X, L, Y, Cy, Lp, D and n are as defined in the specification, are serine protease inhibitors useful as antithrombotic agents.

Abstract: The present invention discloses a mathematical technique which finds substantial utility in electrical engineering, particularly in the general field of data transformation, which occurs in applications such as data encryption and data compression. The technique uses a commencement matrix to transform a first number of a sequence of numbers. This initial transformation forms a forward resultant matrix. Successive transformation of succeeding numbers in the sequence produces for each number in the sequence an augmented forward resultant matrix. Each augmented forward resultant matrix is used to transform the next succeeding number of the sequence, and so on. A final transformed sequence is generated from the final form of the augmented forward resultant matrix.

Abstract: The present invention provides three basic routes for the total synthesis of taxol having the structure: ##STR1## The present invention also provides the intermediates produced in the above processes, processes for synthesizing these intermediates as well as analogues of taxol and nortaxol.